Valuation: AstraZeneca PLC

Market Cap 24TCr 21TCr 19TCr 18TCr 34TCr 22,77800Cr 34TCr 2,28600Cr 89TCr 11,38600Cr 90TCr 88TCr 37,72800Cr P/E 2026 *
19.8x
P/E 2027 * 17.2x
Enterprise Value 26TCr 23TCr 21TCr 19TCr 37TCr 24,68900Cr 37TCr 2,47700Cr 97TCr 12,34100Cr 97TCr 95TCr 40,89300Cr EV / Sales 2026 *
4.1x
EV / Sales 2027 * 3.77x
Free-Float
96.63%
Yield 2026 *
2.15%
Yield 2027 * 2.28%
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-.--% - - 24TCr
+0.69%-7.62%+46.64%+150.88% 1LCr
-0.51%-5.26%+47.74%+49.49% 61TCr
-0.69%-7.50%+23.47%+64.81% 43TCr
+0.48%-2.77%+40.27%+34.96% 35TCr
+0.08%-4.45%+31.74%+39.89% 29TCr
+1.75%-8.29%-1.73%-42.05% 21TCr
+2.00%-1.97%+27.63%+58.40% 20TCr
+0.07%-2.74%+14.09%+66.05% 16TCr
+1.90%+1.43%+8.84%-26.87% 14TCr
Average -0.28%-2.47%+26.52%+43.95% 37.82TCr
Weighted average by Cap. -0.23%-3.63%+34.75%+71.50%

Financials

2026 *2027 *
Net sales 6.33TCr 5.49TCr 5.12TCr 4.71TCr 8.9TCr 6,01800Cr 9TCr 60TCr 24TCr 3,00800Cr 24TCr 23TCr 9,96800Cr 6.68TCr 5.8TCr 5.41TCr 4.97TCr 9.4TCr 6,35800Cr 9.5TCr 64TCr 25TCr 3,17800Cr 25TCr 25TCr 10,53100Cr
Net income 1.21TCr 1.05TCr 978.41Cr 898.81Cr 1.7TCr 1,15000Cr 1.72TCr 12TCr 4.51TCr 57TCr 4.54TCr 4.44TCr 1,90400Cr 1.37TCr 1.19TCr 1.11TCr 1.02TCr 1.93TCr 1,30400Cr 1.95TCr 13TCr 5.12TCr 65TCr 5.15TCr 5.04TCr 2,16000Cr
Net Debt 2.01TCr 1.74TCr 1.63TCr 1.49TCr 2.83TCr 1,91100Cr 2.86TCr 19TCr 7.49TCr 96TCr 7.54TCr 7.38TCr 3,16500Cr 1.23TCr 1.07TCr 995.68Cr 914.68Cr 1.73TCr 1,17000Cr 1.75TCr 12TCr 4.59TCr 58TCr 4.62TCr 4.52TCr 1,93800Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
154.39USD
Average target price
211.35USD
Spread / Average Target
+36.90%

Quarterly revenue - Rate of surprise